# Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

> **NCT00728000** · PHASE2 · WITHDRAWN · sponsor: **University of Cincinnati**

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00728000
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-08
- **Primary completion:** 2009-08
- **Final completion:** 2010-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study withdrawn due to lack of enrollment
- **Last updated:** 2019-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00728000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00728000, "Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00728000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*